CareLit · DOI-Nachweis · Klinische Pädiatrie
MRD-quantification during treatment of ETV6-RUNX1 positive ALL relapses using the genomic breakpoint of the fusion gene
DOI 10.1055/s-0032-1310477
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Hoffmann, M Metzler, A von Stackelberg, C Eckert
ZeitschriftKlinische Pädiatrie
Ausgabe04/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
T-cell receptor (TCR)/Immunoglobulin(IG)-gene rearrangements used as minimal residual disease (MRD) markers in acute lymphoblastic leukaemia (ALL) can describe different subclones at initial/relapse diagnosis because leukaemic clones are exposed to influences of clonal evolution and selection during/after treatment. We aimed at investigating whether the genomic breakpoint of the fusion gene ETV6-RUNX1 (E/R) is a sui…
Zitieren
Zitierempfehlung
J Hoffmann, M Metzler, A von Stackelberg, C Eckert (2012) MRD-quantification during treatment of ETV6-RUNX1 positive ALL relapses using the genomic breakpoint of the fusion gene. Klinische Pädiatrie (04). https://doi.org/10.1055/s-0032-1310477
Mit CareLit weiterarbeiten